EpiBone
EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts grown from a patient's own stem cells using proprietary bioreactor technology, targeting craniofacial reconstruction and orthopedic joint repair patients.
- Company typePrivate
- Founded2013
- HeadquartersJersey City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EpiBone does
EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts from a patient's own stem cells using proprietary bioreactor technology. Founded in 2013 and headquartered in Brooklyn, NY, the company targets skeletal conditions — which it identifies as the leading cause of disability worldwide — by growing living, anatomically precise tissue grafts in approximately 3 weeks (bone) to 4 weeks (cartilage) that are designed to integrate, remodel, and adapt with the patient, eliminating the need for synthetic implants or secondary surgical harvest sites.
The company's technology platform combines CT scan-guided 3D shape customization, stem cell sourcing (from patient abdominal fat for autologous products, from cell banks for allogeneic products), and a proprietary bioreactor that emulates natural tissue development conditions through controlled oxygen, nutrient, and mechanical loading. The pipeline includes three products: EB-CM, an autologous craniofacial bone graft (Phase I/IIa completed in 2023); EB-OC, an allogeneic tissue-engineered osteochondral plug for high-grade cartilage lesions (FDA IND approved for a Phase I/IIb trial in 36 patients); and EB-iAC, an injectable allogeneic cartilage filler for low-grade lesions with up to 2 years of storage stability.
EpiBone is pre-commercial and pre-revenue. Future revenue is expected to come from direct hospital and specialty clinic distribution of patient-specific living tissue grafts to oral/maxillofacial surgeons, orthopedic sports medicine specialists, and craniofacial reconstruction teams — a procedure-linked, high-value model analogous to advanced biologics and cell therapy commercialization. The company has raised approximately $35M+ across multiple funding rounds from 2014 through 2025, with backing from NetScientific PLC, Kendall Capital Partners, Covenant Venture Capital, Tachyon Ventures, Plum Alley, Breakout Labs, and others. Strategic and academic ties to Columbia University (co-founder origin, board representation) and MIT (Dr. Robert Langer on the board) reinforce its research foundation.
EpiBone firmographics
Firmographics- Name
- EpiBone
- Legal name
- EpiBone, Inc.
- Website
- https://epibone.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EpiBone is a clinical-stage regenerative medicine company developing personalized bone and cartilage grafts grown from a patient's own stem cells using proprietary bioreactor technology, targeting craniofacial reconstruction and orthopedic joint repair patients.
- Ownership category
- akta.pro rank
EpiBone industry classification
Industry- Product category
- Tissue Engineering
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Dental Implant Surgery & Bone Grafting (HLABAEAB)
Keywords
Where EpiBone is headquartered
LocationHeadquarters
- HQ city
- Jersey City
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EpiBone business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Regenerative Tissue Products (Pipeline): EpiBone is a pre-commercial, clinical-stage company. Its revenue model will derive from the sale of personalized, tissue-engineered bone and cartilage grafts. Products EB-CM (autologous craniofacial bone), EB-OC (osteochondral plug), and EB-iAC (injectable cartilage) are in various stages of clinical development. Revenue will come from direct supply of patient-specific living tissue grafts to hospital systems, orthopedic surgeons, and oral/maxillofacial surgeons — a high-value, procedure-linked model akin to advanced biologics and cell therapy commercialization.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels3 records
EpiBone product offering
Product offeringCore offering
EpiBone is a clinical-stage regenerative medicine company that grows personalized bone and cartilage grafts from a patient's own stem cells (or donor-derived cells for allogeneic products) using proprietary bioreactor technology and 3D bioprinting. Its pipeline includes EB-CM (autologous craniofacial bone graft), EB-OC (allogeneic osteochondral plug), and EB-iAC (injectable allogeneic cartilage), each cultivated in 3-4 weeks for skeletal reconstruction procedures.
Product overview
EpiBone is a regenerative medicine company offering a platform of tissue-engineered bone and cartilage products grown from stem cells using proprietary bioreactor technology. The product portfolio consists of three core offerings: EB-CM for craniofacial bone reconstruction, EB-OC for osteochondral joint repair, and EB-iAC for injectable cartilage treatment. All products leverage stem cell extraction, 3D customization via CT scanning, and bioreactor-based tissue growth to create personalized, living tissue grafts that eliminate the need for artificial implants.
Differentiator
Problem solved
Functional benefit
Products and services
- EB-CM (EpiBone-Craniomaxillofacial) Tissue-engineered autologous bone graft product for craniofacial defects resulting from trauma, congenital defects, or degenerative bone disease. Customized for patients via CT scan with stem cells extracted from patients' abdominal fat and cultivated in a proprietary bioreactor. Indicated for facial bone reconstruction procedures performed by oral and maxillofacial surgeons.
- EB-OC (EpiBone-Osteochondral) Allogeneic, tissue-engineered osteochondral plug for treating high-grade cartilage lesions in healthy joints. Composed of condensed mesenchymal cells from donor bone marrow encapsulated in hydrogel and cultivated on a bone scaffold in a bioreactor with cyclical mechanical loading and perfusion. Designed for orthopedic sports medicine and joint surgery specialists.
- EB-iAC (EpiBone-injectable Articular Cartilage) Allogeneic, injectable cartilage product for treating low-grade cartilage lesions that do not involve underlying bone. Stem cells from a cell bank are processed into condensed mesenchymal cells primed for cartilage formation, combined with a hydrogel carrier, and delivered via injection. Components can be stored for up to 2 years.
Quantifiable outcome
- Craniofacial bone reconstruction using tissue-engineered autologous grafts — Phase I/IIa clinical trial completed 2023
- +4 more outcomes
Companies that use EpiBone
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
EpiBone technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
EpiBone partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Columbia UniversitycoreEpiBone originated from Columbia University research. Co-Founders Dr. Nina Tandon and Dr. Sarindr Bhumiratana completed their PhDs and postdocs at Columbia. Board member Dr. Gordana Vunjak-Novakovic directs the Laboratory for Stem Cells & Tissue Engineering at Columbia. The company leverages Columbia's research infrastructure and academic talent pipeline.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
EpiBone competitors and assessment
Company assessmentBroad incumbents
- Bioventus: Bioventus offers orthobiologic solutions including bone graft substitutes and cartilage repair products. Comparable as a commercial-stage orthobiologics incumbent serving overlapping orthopedic surgeon customers, though with synthetic/allograft rather than living-cell technology.
- Stryker: Stryker is a global orthopedics and medical device leader with significant investments in regenerative and biologic solutions for bone and joint repair. Comparable as a large incumbent whose sports medicine and orthobiologics franchises compete with EpiBone's target surgeon customers.
- Organogenesis: Organogenesis is a leading regenerative medicine company commercializing living-cell-based wound care and surgical biologics (Apligraf, Dermagraft). Comparable as a broader commercial-stage regenerative medicine incumbent using living cell-based products, though focused on skin/soft tissue rather than skeletal.
- Integra LifeSciences: Integra LifeSciences develops regenerative tissue technologies including dural repair and dermal regeneration products using collagen and tissue-engineering approaches. Comparable as a diversified regenerative medicine incumbent with overlapping surgical customer channels.
- Smith+Nephew (CartiHeal): Smith+Nephew acquired CartiHeal (Agili-C), an FDA-approved cartilage repair implant, positioning them in the regenerative cartilage space. Comparable as a major orthopedic incumbent actively building a cartilage regeneration portfolio through M&A.
Emerging players
- MiMedx: MiMedx develops placental tissue allografts for wound care and surgical applications in regenerative medicine. Comparable as an emerging peer in the regenerative tissue space serving surgical specialties with biologically-derived grafts.
Direct peers
- Vericel: Vericel markets MACI, an FDA-approved autologous cultured chondrocyte implant for cartilage repair of the knee — the closest direct competitor to EpiBone's EB-OC osteochondral plug and EB-iAC injectable cartilage products, with an established US commercial infrastructure in sports medicine.
- Mesoblast: Mesoblast develops allogeneic cellular medicines for inflammatory and orthopedic conditions, including cartilage and bone indications. Comparable as a clinical/late-stage cell therapy company targeting musculoskeletal regeneration with stem-cell-based platforms.
- Histogenics (now Ocugen via merger; NeoCart legacy): Histogenics developed NeoCart, an autologous tissue-engineered cartilage implant — directly analogous in product concept (patient-specific, cell-based cartilage graft) to EpiBone's EB-OC. Acquired/merged with Ocugen; serves as a reference case for the cartilage tissue engineering space.
- CartiHeal (now part of Smith+Nephew): CartiHeal developed the Agili-C cartilage repair scaffold, now FDA-approved and acquired by Smith+Nephew. Comparable as a direct cartilage regeneration product peer targeting similar orthopedic indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
EpiBone social profiles
Digital presenceEpiBone financial estimates
Financial estimateRevenue estimate
Valuation estimate
EpiBone leadership team
Management profileNumber of profiles
Profiles4 records
EpiBone funding detail
Funding detailFunding overview
Funding rounds16 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EpiBone M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EpiBone
What does EpiBone do?
EpiBone is a clinical-stage regenerative medicine company that grows personalized bone and cartilage grafts from a patient's own stem cells (or donor-derived cells for allogeneic products) using proprietary bioreactor technology and 3D bioprinting. Its pipeline includes EB-CM (autologous craniofacial bone graft), EB-OC (allogeneic osteochondral plug), and EB-iAC (injectable allogeneic cartilage), each cultivated in 3-4 weeks for skeletal reconstruction procedures.
Is EpiBone a public or private company?
EpiBone is a private company. It is classified as venture growth investor backed and is currently operating.
When was EpiBone founded?
EpiBone was founded in 2013. It employs 11 to 50 people.
Where is EpiBone based?
EpiBone is headquartered in Jersey City, United States, in the North America region.
How does EpiBone make money?
One revenue line is on record: regenerative Tissue Products (Pipeline).
Who are EpiBone's main competitors?
Broad incumbents on record are Bioventus, Stryker, Organogenesis, Integra LifeSciences and Smith+Nephew (CartiHeal). MiMedx is listed as an emerging player. Direct peers are Vericel, Mesoblast, Histogenics (now Ocugen via merger; NeoCart legacy) and CartiHeal (now part of Smith+Nephew).
Does EpiBone have an API?
No public API is recorded for EpiBone.
What industry is EpiBone in?
EpiBone's product category is Tissue Engineering. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 334510 and its SIC code is 3842.